Compare BAC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAC | NVO |
|---|---|---|
| Founded | 1784 | 1923 |
| Country | United States | Denmark |
| Employees | 213000 | 69500 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.6B | 197.4B |
| IPO Year | N/A | N/A |
| Metric | BAC | NVO |
|---|---|---|
| Price | $57.74 | $47.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 11 |
| Target Price | ★ $60.34 | $51.00 |
| AVG Volume (30 Days) | ★ 36.0M | 12.0M |
| Earning Date | 04-15-2026 | 05-06-2026 |
| Dividend Yield | 2.12% | ★ 3.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.11 | N/A |
| Revenue Next Year | $5.80 | $3.70 |
| P/E Ratio | $14.01 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.75 | $35.12 |
| 52 Week High | $58.33 | $71.80 |
| Indicator | BAC | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 72.83 | 64.55 |
| Support Level | $51.20 | $45.62 |
| Resistance Level | N/A | $47.79 |
| Average True Range (ATR) | 1.09 | 1.39 |
| MACD | 0.32 | 0.40 |
| Stochastic Oscillator | 90.14 | 95.31 |
Bank of America is a formidable financial titan with a $3.5 trillion balance sheet and a cornerstone of the American economy, holding the second-largest deposit market share in the United States. While the firm has maintained its stronghold among middle-market and retail clientele domestically, Bank of America has continued to hold its own on the global stage, as evidenced by its fourth-largest global trading operation and an investment banking division that regularly finishes in the top four in global league tables. The firm is organized across four segments: consumer banking, global wealth and investment management, global banking, and global markets.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.